An Open-Label Pilot Study Using Thioguanine as a Therapeutic Alternative in Crohn's Disease Patients Resistant to 6-Mercaptopurine Therapy
Open Access
- 1 August 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 7 (3) , 181-189
- https://doi.org/10.1097/00054725-200108000-00001
Abstract
SummaryBackground and Aims. A substantial number of patients with inflammatory bowel disease (IBD) fail to achieve a complete clinical response with 6-mercaptoKeywords
This publication has 32 references indexed in Scilit:
- Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug AdministrationAmerican Journal of Gastroenterology, 2000
- A controlled double blind study of azathioprine in the management of Crohn's disease.Gut, 1995
- Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemiaThe Lancet, 1994
- Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?British Journal of Cancer, 1993
- The clinical pharmacology of 6-mercaptopurineEuropean Journal of Clinical Pharmacology, 1992
- Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.BMJ, 1992
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990
- Favorable effect of 6-Mercaptopurine on fistulae of Crohn's diseaseDigestive Diseases and Sciences, 1985
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980
- CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASEPublished by Elsevier ,1971